N/A
Manufactured by Kobayashi Healthcare International, Inc.
77,880 FDA adverse event reports analyzed
Last updated: 2026-04-14
CAFFEINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kobayashi Healthcare International, Inc.. The most commonly reported adverse reactions for CAFFEINE include TOXICITY TO VARIOUS AGENTS, FATIGUE, PAIN, OFF LABEL USE, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CAFFEINE.
Out of 7,451 classified reports for CAFFEINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 77,880 FDA FAERS reports that mention CAFFEINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TOXICITY TO VARIOUS AGENTS, FATIGUE, PAIN, OFF LABEL USE, VOMITING, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Kobayashi Healthcare International, Inc. in connection with CAFFEINE. Always verify the specific product and NDC with your pharmacist.